Autolus Therapeutics Secures 10-Year Critical Lentiviral Vector Supply Agreement with AGC Biologics
Summary
Autolus Therapeutics plc has entered into a 10-year Master Supply Agreement with AGC Biologics for the critical lentiviral vector, essential for its CAR-T product manufacturing, including AUCATZYL.
Key Events
-
Long-Term Supply Secured
Autolus Limited, a wholly-owned subsidiary, signed a 10-year Master Supply Agreement with AGC Biologics for the manufacture and supply of lentiviral vector.
-
Critical Raw Material
The lentiviral vector is a critical raw material for manufacturing Autolus's CAR-T products, including the commercial AUCATZYL and clinical trial products.
-
Significant Financial Commitment
The agreement includes a minimum purchase commitment of 14 batches in the first two years and at least EUR 25 million in products and services over the subsequent five-year period.
-
Strategic Partnership
AGC Biologics also gains the first right to negotiate new manufacturing activities for Autolus's obe-cel product.
Analysis
Autolus Therapeutics plc has entered into a 10-year Master Supply Agreement with AGC Biologics for the critical lentiviral vector, essential for its CAR-T product manufacturing, including AUCATZYL. This agreement significantly de-risks Autolus's manufacturing supply chain by securing a long-term source for a critical raw material. The commitment of at least EUR 25 million over five years (following an initial two-year period) highlights the strategic importance of this partnership. This ensures stability for the production of its commercial CAR-T product, AUCATZYL, and its clinical pipeline, which is a positive operational development for the company.
At the time of this filing, AUTL was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $388.6M. The 52-week trading range was $1.11 to $2.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.